Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1093819-32-9

Post Buying Request

1093819-32-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1093819-32-9 Usage

General Description

3-Amino-5-bromo-2-ethylpyridine is a chemical compound with the molecular formula C8H10BrN2. It is a derivative of pyridine and is commonly used as an intermediate in the synthesis of pharmaceutical compounds and agrochemicals. 3-AMino-5-broMo-2-ethylpyridine is characterized by its high reactivity due to the presence of the amino and bromo functional groups, making it a versatile building block for various organic reactions. It is also known for its potential biological activities, and its derivatives have been studied for their potential as anti-cancer, anti-inflammatory, and anti-bacterial agents. Overall, 3-Amino-5-bromo-2-ethylpyridine is a valuable chemical in the field of medicinal chemistry and organic synthesis.

Check Digit Verification of cas no

The CAS Registry Mumber 1093819-32-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,8,1 and 9 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1093819-32:
(9*1)+(8*0)+(7*9)+(6*3)+(5*8)+(4*1)+(3*9)+(2*3)+(1*2)=169
169 % 10 = 9
So 1093819-32-9 is a valid CAS Registry Number.

1093819-32-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-bromo-2-ethylpyridin-3-amine

1.2 Other means of identification

Product number -
Other names 3-AMINO-5-BROMO-2-ETHYLPYRIDINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1093819-32-9 SDS

1093819-32-9Downstream Products

1093819-32-9Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

Li, Zhanhui,Hao, Yongjin,Yang, Chengkui,Yang, Qing,Wu, Shuwei,Ma, Haikuo,Tian, Sheng,Lu, Haohao,Wang, Jingrui,Yang, Tao,He, Sudan,Zhang, Xiaohu

, (2021/12/16)

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

HETEROARYLS AND USES THEREOF

-

Paragraph 00230, (2015/08/03)

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

-

Page/Page column 84, (2009/01/23)

Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1093819-32-9